Role of Omega-6 Fatty Acids in Hepatocellular Carcinoma Development. (RO6-HCC)

Sohag University

Status: Not yet enrolling

Conditions: Carcinoma, Hpatocellular

Treatments: Dietary Supplement: Omega 6 fatty acid

Study type: Observational

Funder types: Other

Identifiers

NCT07265076

Soh-Med--25-10-6MS (Registry Identifier)

06-HCC-Study-2025-A

Details and patient eligibility

About

This observational study investigates the association between serum Omega-6 fatty acids and hepatocellular carcinoma development. Adult HCC patients and age - and gender matched healthy controls will be included. Serum Omega-6 levels will be compared between groups to explore potential correlations with disease presence and severity .

Full description

Hepatocellular carcinoma is a leading cause of cancer related deaths worldwide . Omega-6 fatty acids have been suggested to influence liver cancer development .This observational study aims to assess the association between serum Omega-6 fatty acid levels and HCC development .

Adult patients diagnosed with HCC will be recruited from Sohag University Hospital, along with age and gender matched healthy controls . Blood samples will be collected to measure serum Omega-6 levels using standardized bio-chemical assays . clinical and laboratory data , including liver function tests and tumor stage , will also be recorded.

The study will compare Omega-6 levels between HCC patients and controls , and analyze potential correlation with disease severity .Findings may provide insights into the role of Omega-6 fatty acids in HCC pathogenesis and help identify biomarkers for early detection and risk assessment .

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 1. Adults aged 18 years and above. 2. Patients with hepatocellular carcinoma (confirmed clinically, laboratory, radiologically, or histopathologically).

  3. Ability and willingness to provide informed written consent. 4. For healthy controls: individuals without liver disease or history of malignancy, matched by age and gender.

  5. For cirrhotic controls: patients with liver cirrhosis without evidence of any malignancy, matched by age and gender.

Exclusion criteria

1. History of chronic inflammatory (except for liver cirrhosis or HCC) or autoimmune diseases.

2. Current use of omega-6 or omega-3 fatty acid supplements.

3. Presence of other types of cancer.

4. Pregnant or lactating women.

5. presence of severe comorbid condition.

   -

Trial design

100 participants in 2 patient groups

HCC Patients 50-100

HCC Patients Healthy Controls

Description:

HCC Patients: adult patients diagnosed with Hepatocellular carcinoma , meeting inclusion/exclusion criteria healthy controls: age and gender matched healthy adults with no history of liver disease

Treatment:

Dietary Supplement: Omega 6 fatty acid